ValuEngine upgraded shares of Natus Medical (NASDAQ:BABY) from a hold rating to a buy rating in a research note issued to investors on Thursday.

BABY has been the topic of several other reports. Zacks Investment Research upgraded shares of Natus Medical from a sell rating to a hold rating in a research report on Tuesday, December 25th. BidaskClub lowered shares of Natus Medical from a buy rating to a hold rating in a research report on Thursday, December 13th. Finally, Roth Capital set a $36.00 target price on shares of Natus Medical and gave the stock a buy rating in a research report on Thursday, October 25th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $42.50.

BABY traded down $0.06 on Thursday, hitting $34.32. 206,440 shares of the company were exchanged, compared to its average volume of 311,055. The company has a current ratio of 2.62, a quick ratio of 1.89 and a debt-to-equity ratio of 0.23. Natus Medical has a fifty-two week low of $27.69 and a fifty-two week high of $37.95. The firm has a market capitalization of $1.15 billion, a P/E ratio of 23.65 and a beta of 0.53.

Natus Medical (NASDAQ:BABY) last issued its earnings results on Wednesday, October 24th. The medical equipment provider reported $0.40 earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.02). Natus Medical had a positive return on equity of 11.34% and a negative net margin of 3.53%. The company had revenue of $130.60 million for the quarter, compared to analyst estimates of $132.92 million. During the same quarter in the previous year, the company posted $0.40 earnings per share. The company’s quarterly revenue was up 6.5% compared to the same quarter last year. Analysts predict that Natus Medical will post 1.48 EPS for the current year.

In other Natus Medical news, Director Robert A. Gunst sold 14,750 shares of the company’s stock in a transaction dated Monday, November 19th. The shares were sold at an average price of $33.54, for a total value of $494,715.00. Following the sale, the director now owns 32,392 shares of the company’s stock, valued at $1,086,427.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ken Ludlum sold 30,000 shares of the company’s stock in a transaction dated Thursday, November 29th. The shares were sold at an average price of $31.02, for a total transaction of $930,600.00. Following the completion of the sale, the director now directly owns 73,957 shares in the company, valued at approximately $2,294,146.14. The disclosure for this sale can be found here. 5.50% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. lifted its stake in shares of Natus Medical by 4.6% during the third quarter. BlackRock Inc. now owns 5,013,693 shares of the medical equipment provider’s stock valued at $178,739,000 after buying an additional 220,521 shares during the period. Janus Henderson Group PLC lifted its stake in shares of Natus Medical by 14.6% during the third quarter. Janus Henderson Group PLC now owns 3,111,761 shares of the medical equipment provider’s stock valued at $110,934,000 after buying an additional 396,772 shares during the period. Vanguard Group Inc lifted its stake in shares of Natus Medical by 2.3% during the third quarter. Vanguard Group Inc now owns 2,612,432 shares of the medical equipment provider’s stock valued at $93,133,000 after buying an additional 58,239 shares during the period. Vanguard Group Inc. lifted its stake in shares of Natus Medical by 2.3% during the third quarter. Vanguard Group Inc. now owns 2,612,432 shares of the medical equipment provider’s stock valued at $93,133,000 after buying an additional 58,239 shares during the period. Finally, Eagle Asset Management Inc. lifted its stake in shares of Natus Medical by 6.8% during the third quarter. Eagle Asset Management Inc. now owns 1,924,407 shares of the medical equipment provider’s stock valued at $68,605,000 after buying an additional 123,132 shares during the period. 94.45% of the stock is currently owned by institutional investors.

About Natus Medical

Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Further Reading: Insider Trading – What You Need to Know

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.